Crohn’s Disease Therapeutics Market Projected to Reach USD 11.16 Billion by 2030
Advancements in Non-Surgical Treatments and Rising Disease Prevalence Drive Market Expansion
The Crohn’s Disease Therapeutics Market Growth is poised for significant growth, with projections indicating a rise from USD 7.47 billion in 2023 to approximately USD 11.16 billion by 2030. This represents a Compound Annual Growth Rate (CAGR) of 5.9% over the forecast period. The surge is primarily attributed to the increasing prevalence of Crohn's disease and continuous advancements in therapeutic options.
Important points to note are: Click here to obtain a PDF sample copy of this report :
https://www.maximizemarketresearch.com/request-sample/121644/
Market Definition and Estimation
Crohn's disease is a chronic inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, leading to symptoms such as abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The inflammation often penetrates deep into the layers of affected bowel tissue, resulting in debilitating and sometimes life-threatening complications.
The market valuation reflects the growing demand for effective treatments, driven by the rising incidence of Crohn's disease globally. Factors such as industrialization, environmental changes, dietary shifts, smoking, and genetic predispositions have contributed to this increase, particularly in developing countries. According to the Centers for Disease Control and Prevention (CDC), approximately 1.8 million Americans are affected by IBD annually.
Market Growth Drivers and Opportunities
Several key factors are propelling the growth of the Crohn’s Disease Therapeutics Market:
Rising Disease Prevalence: The increasing number of Crohn's disease cases worldwide necessitates the development and availability of effective therapeutic options.
Advancements in Non-Surgical Treatments: Innovations in non-surgical therapies, including the development of biosimilars and novel biological agents, offer effective treatment alternatives with improved safety profiles. Biosimilars, in particular, provide cost-effective options, enhancing patient access to advanced therapies.
Strategic Collaborations and Acquisitions: Major pharmaceutical companies are engaging in partnerships and acquisitions to bolster their therapeutic portfolios. For instance, Eli Lilly's acquisition of Morphic Holding for $3.2 billion aims to enhance its capabilities in producing treatments for inflammatory bowel diseases, including Crohn's disease.
Regulatory Approvals of New Therapies: The approval of new therapeutic agents expands the treatment landscape. Eli Lilly's Omvoh, for example, received U.S. FDA approval for treating moderate-to-severe Crohn's disease in adults, demonstrating significant efficacy in clinical trials.
Browse Full report :
https://www.maximizemarketresearch.com/market-report/crohns-disease-therapeutics-market/121644/
About Maximize Market Research:
Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.
Contact Maximize Market Research:
3rd Floor, Navale IT Park, Phase 2
Pune Banglore Highway, Narhe,
Pune, Maharashtra 411041, India
sales@maximizemarketresearch.com
+91 9607365656
Crohn’s Disease Therapeutics Market Projected to Reach USD 11.16 Billion by 2030
Advancements in Non-Surgical Treatments and Rising Disease Prevalence Drive Market Expansion
The Crohn’s Disease Therapeutics Market Growth is poised for significant growth, with projections indicating a rise from USD 7.47 billion in 2023 to approximately USD 11.16 billion by 2030. This represents a Compound Annual Growth Rate (CAGR) of 5.9% over the forecast period. The surge is primarily attributed to the increasing prevalence of Crohn's disease and continuous advancements in therapeutic options.
Important points to note are: Click here to obtain a PDF sample copy of this report : https://www.maximizemarketresearch.com/request-sample/121644/
Market Definition and Estimation
Crohn's disease is a chronic inflammatory bowel disease (IBD) that causes inflammation of the digestive tract, leading to symptoms such as abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The inflammation often penetrates deep into the layers of affected bowel tissue, resulting in debilitating and sometimes life-threatening complications.
The market valuation reflects the growing demand for effective treatments, driven by the rising incidence of Crohn's disease globally. Factors such as industrialization, environmental changes, dietary shifts, smoking, and genetic predispositions have contributed to this increase, particularly in developing countries. According to the Centers for Disease Control and Prevention (CDC), approximately 1.8 million Americans are affected by IBD annually.
Market Growth Drivers and Opportunities
Several key factors are propelling the growth of the Crohn’s Disease Therapeutics Market:
Rising Disease Prevalence: The increasing number of Crohn's disease cases worldwide necessitates the development and availability of effective therapeutic options.
Advancements in Non-Surgical Treatments: Innovations in non-surgical therapies, including the development of biosimilars and novel biological agents, offer effective treatment alternatives with improved safety profiles. Biosimilars, in particular, provide cost-effective options, enhancing patient access to advanced therapies.
Strategic Collaborations and Acquisitions: Major pharmaceutical companies are engaging in partnerships and acquisitions to bolster their therapeutic portfolios. For instance, Eli Lilly's acquisition of Morphic Holding for $3.2 billion aims to enhance its capabilities in producing treatments for inflammatory bowel diseases, including Crohn's disease.
Regulatory Approvals of New Therapies: The approval of new therapeutic agents expands the treatment landscape. Eli Lilly's Omvoh, for example, received U.S. FDA approval for treating moderate-to-severe Crohn's disease in adults, demonstrating significant efficacy in clinical trials.
Browse Full report : https://www.maximizemarketresearch.com/market-report/crohns-disease-therapeutics-market/121644/
About Maximize Market Research:
Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.
Contact Maximize Market Research:
3rd Floor, Navale IT Park, Phase 2
Pune Banglore Highway, Narhe,
Pune, Maharashtra 411041, India
sales@maximizemarketresearch.com
+91 9607365656
